1-(3-Oxetanyl)-4-(4-piperidinyl)piperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(3-Oxetanyl)-4-(4-piperidinyl)piperazine
• 英文别名: 1-(oxetan-3-yl)-4-piperidin-4-ylpiperazine
• 化学式: C₁₂H₂₃N₃O
• 分子量: 225.33
• InChiKey: VINXFYMHTYOBOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  27.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] OXINDOLE DERIVATIVES CARRYING AN OXETANE SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSINE-RELATED DISEASES<br/>[FR] DÉRIVÉS D'OXINDOLE À SUBSTITUANT OXÉTANE ET LEUR UTILISATION POUR LE TRAITEMENT DE MALADIES LIÉES À LA VASOPRESSINE
  申请人：ABBVIE DEUTSCHLAND

  公开号：WO2014140186A1

  公开（公告）日：2014-09-18

  The present invention relates to novel substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-related disorders.

  本发明涉及新型替代氧吲哚衍生物，包括它们的药物组合物，以及它们用于治疗与加压素相关的疾病的用途。
• Oxindole Derivatives Carrying An Oxetane Substituent and Use Thereof For Treating Vassopressin-Related Diseases
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US20140315918A1

  公开（公告）日：2014-10-23

  The present invention relates to novel substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-related disorders.

  本发明涉及新型取代的氧化吲哚衍生物，包括它们的药物组成物，以及它们用于治疗与加压素相关的疾病的用途。
• OXINDOLE DERIVATIVES CARRYING AN OXETANE SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US20160168135A1

  公开（公告）日：2016-06-16

  The present invention relates to novel substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-related disorders.

  本发明涉及新型取代的氧化吲哚衍生物，包括它们的药物组合物，以及它们用于治疗与加压素相关的疾病的应用。
• AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Beijing Adamadle Biotechnology Limited Liability Company

  公开号：EP3640248A1

  公开（公告）日：2020-04-22

  The present invention relates to an aminopyrimidine compound, a preparation method therefor and use thereof. The aminopyrimidine compound has the structure as shown in formula I: the compound is an inhibitor of an epidermal growth factor receptor (EGFR) kinase. The present invention also relates to a pharmaceutical composition containing the compounds, a method for preparing same and the use of same in preparation of anti-tumor drugs.

  本发明涉及一种氨基嘧啶化合物、其制备方法及其用途。氨基嘧啶化合物的结构如式 I 所示： 该化合物是表皮生长因子受体（EGFR）激酶的抑制剂。本发明还涉及一种含有上述化合物的药物组合物、其制备方法和在制备抗肿瘤药物中的用途。
• Aminopyrimidine compound, preparation method therefor and use thereof
  申请人：BEIJING ADAMADLE BIOTECHNOLOGY LIMITED LIABILITY COMPANY

  公开号：US11352352B2

  公开（公告）日：2022-06-07

  The present invention relates to an aminopyrimidine compound, a preparation method therefor and use thereof. The aminopyrimidine compound has the structure as shown in formula I: the compound is an inhibitor of an epidermal growth factor receptor (EGFR) kinase. The present invention also relates to a pharmaceutical composition containing the compounds, a method for preparing same and the use of same in preparation of anti-tumor drugs.

  本发明涉及一种氨基嘧啶化合物、其制备方法及其用途。氨基嘧啶化合物的结构如式 I 所示： 该化合物是表皮生长因子受体（EGFR）激酶的抑制剂。本发明还涉及一种含有上述化合物的药物组合物、制备方法以及在制备抗肿瘤药物中的应用。